Last Close
Jun 12  •  04:00PM ET
4.29
Dollar change
-0.41
Percentage change
-8.72
%
Jun 11, 9:35 AMCo-Diagnostics signs exclusive five-year Mexico distribution deal for Co-Dx PCR Pro point-of-care platform
Index
-
P/E
-
EPS (ttm)
-28.01
Insider Own
5.35%
Shs Outstand
3.60M
Perf Week
-23.80%
Market Cap
15.81M
Forward P/E
-
EPS next Y
-
Insider Trans
0.00%
Shs Float
3.49M
Perf Month
168.12%
Enterprise Value
9.61M
PEG
-
EPS next Q
-
Inst Own
7.78%
Perf Quarter
53.21%
Income
-48.50M
P/S
31.00
EPS this Y
-
Inst Trans
-7.55%
Perf Half Y
-60.03%
Sales
0.51M
P/B
0.96
EPS next Y
-
ROA
-126.56%
Perf YTD
-15.18%
Book/sh
4.45
P/C
1.92
EPS next 5Y
-
ROE
-151.66%
52W High
46.50 -90.77%
Perf Year
-50.86%
Cash/sh
2.23
P/FCF
-
EPS past 3/5Y
-37.47% -
ROIC
-281.74%
52W Low
1.26 240.48%
Perf 3Y
-86.76%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
-76.97% -64.54%
Gross Margin
-187.30%
Volatility
21.15% 39.80%
Perf 5Y
-98.38%
Dividend TTM
-
EV/Sales
18.84
EPS Y/Y TTM
18.03%
Oper. Margin
-6255.15%
ATR (14)
1.62
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
2.09
Sales Y/Y TTM
-9.46%
Profit Margin
-9438.49%
RSI (14)
48.79
Dividend Gr. 3/5Y
- -
Current Ratio
2.28
EPS Q/Q
42.48%
SMA20
-17.76%
Beta
2.86
Payout
-
Debt/Eq
0.13
Sales Q/Q
190.30%
SMA50
40.48%
Rel Volume
0.07
Prev Close
4.70
Employees
115
LT Debt/Eq
0.07
SMA200
-33.62%
Avg Volume
6.47M
Price
4.29
IPO
Jul 12, 2017
Option/Short
No / Yes
Trades
Volume
433,133
Change
-8.72%
Jun-11-26 09:00AM
Jun-02-26 09:00AM
May-26-26 01:00PM
09:00AM
May-19-26 10:54PM
10:34AM Loading…
10:34AM
May-15-26 08:30AM
01:02AM
May-14-26 04:01PM
May-11-26 05:43AM
May-08-26 09:00AM
Apr-16-26 09:00AM
Apr-14-26 09:00AM
Apr-09-26 09:00AM
Apr-02-26 09:00AM
08:30AM Loading…
Apr-01-26 08:30AM
Mar-31-26 11:02PM
04:01PM
Mar-25-26 08:00AM
Mar-20-26 03:30PM
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
ChairmanMr. Dwight H. Egan
PresidentMr. Richard David Abbott
CFO & Company SecretaryMr. Brian L. Brown CPA
Chief Operating OfficerMr. David Nielsen
Vice President of Finance & AccountingMr. Dan Bohrer CPA